Takeda and Dr. Reddy’s Laboratories Enter Into Exclusive Collaboration to Promote and Distribute QDENGA® in India’s Pediatric and Adult Private Market
Takeda Pharmaceutical and Dr. Reddy’s Laboratories have signed an agreement to distribute the QDENGA dengue vaccine in India's private market. The vaccine is expected to be available by early 2027 for individuals aged 4-60.
Why it matters
This partnership addresses the rising public health challenge of dengue in India by increasing access to the country's first approved vaccine.
Hyderabad, Telangana, Mumbai, Maharashtra, India --- Business Wire India
Takeda Pharmaceutical Company Limited, through its Indian subsidiary Takeda Biopharmaceuticals India Private Limited (together referred to as “Takeda”) and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today entered into a distribution agreement under which Dr. Reddy’s will promote and distribute Takeda’s dengue vaccine, QDENGA®, across India’s private market for pediatric and adult vaccination in India. Subject to completion of applicable processes with local authorities, the vaccine is anticipated to become available in the first half of 2027.
The collaboration follows the approval of QDENGA’s marketing authorization by India’s Central Drugs Standard Control Organization (CDSCO) in July 2026 for individuals aged 4-60 years. As India’s first approved dengue vaccine, the approval marks an important milestone in the country’s efforts to strengthen dengue prevention and management.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in